Peter DeMuth - Feb 1, 2024 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role
Chief Scientific Officer
Signature
/s/Peter DeMuth
Stock symbol
ELTX
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 06:01 AM
Previous filing
Jun 7, 2023
Next filing
Oct 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Stock Option (right to buy) Award $0 +29.8K $0.00 29.8K Feb 1, 2024 Common Stock 29.8K $4.50 Direct F1
transaction ELTX Stock Option (right to buy) Award $0 +342 $0.00 342 Feb 1, 2024 Common Stock 342 $4.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F2 The stock options vested in full on February 1, 2024.